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Boundary layer infusion of heparin prevents 
thrombosis and reduces neointimal 
hyperplasia in venous polytetrafluoroethylene 
grafts without systemic anticoagulation 
Changyi Chen, MD, Stephen R. Hanson, PhD, and Man B. Lumsden, MB, ChB, 
Atlanta, Ga. 
F'urpose: Recently, we designed and characterized a novel polytetraßuoroethylene-based 
local drug delivery device that selectively concentrates infused pharmacologic agents 
specifically within those blood layers adjacent o the graft wall and at downstream 
anastomotic sites. In this study we locaUy administered heparin with this approach and 
evaluated its effect on graft patency and eointimal hyperplasia formation in a rabbit model 
of inferior vena cava replacement. 
3~ethods: Twelve animals were evenly assigned ither to a control group infiased with saline 
solution or to a treatment group infused with heparin for 14 days. Bromodeoxyuridine 
labeling was used to assess vascular cell proliferation. 
R~sults: All grafts in the control group were occluded at 14 days. All grafts in the 
heparin-treated group remained patent, although there was no significant difference in 
systemic activated partial thromboplastin time measurements taken before and during the 
hafusion of heparin (p > 0.5). In the treatment group, heparin reduced neointimal 
thickness, neointimal area, and the bromodeoxyuridine labeling index by 88%, 95%, and 
72%, respectively (p < 0.01), at the locally treated ownstream anastomosis a compared 
with the untreated upstream anastomosis. 
Conclusion: These data demonstrate hat the local boundary layer infusion of heparin 
significantly increases overall inferior vena cava graft patency (p = 0.014) and markedly 
reduces downstream anastomotic neointimal hyperplasia nd cell proliferation. This 
approach may represent an attractive strategy for antithrombotic therapy in venous 
replacement with synthetic graft materials. (J VASC SURG 1995;22:237-47.) 
Obstructive venous disease isa common sequel of 
lower extremity deep venous thrombosis and in some 
cases may be treated by vein replacement. Venous 
replacement conduits are also required after local 
resection for trauma or neoplasia. Although autog- 
enous vein grafts have provided the most consistent 
success, their use is frequently impractical because of 
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lack of availability, size mismatch, or concurrent 
disease. Furthermore, the harvesting of collateral 
venous conduits can potentially exacerbate he task. 
In addition, autogenous graft material of adequate 
diameter is not available for reconstruction f the 
major veins. Consequently, a prosthetic graft is 
desirable. At present, the most widely accepted 
synthetic prosthesis i comprised of expanded poly- 
tetrafluoroethylene (ePTFE). ePTFE has been used 
for segmental venous replacement of the superior 
vena cava, 1'2 portal vein, 3,4 external i iac, and other 
extremity veins -8 and for reconstruction f hepatic 
and renal veins in organ transplantation. 9a° With 
large-caliber veins, such as the human vena cava, 
reported patency rates appear promising. However, 
low succcss rates have consistently been obtained for 
replacement or reconstruction of smaller-caliber 
veins such as the femoral vein. The limited use of 
prosthetic graft materials in the venous system has 
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been primarily due to early graft thrombosis and the 
frequent latc occurrence of suture line stenosis. 11,12 
Low pressure, low velocity blood flow, and the 
inherent thrombogenicity of prosthetic materials all 
contribute to the thrombogenic environment expe- 
rienced by synthetic venous grafts. 13-14 To increase 
blood flow rates through venous grafts, the use of a 
temporary distal arteriovenous fi tula has been sug- 
gested. 15,16 To avoid graft occlusion cansed by 
gradual and progressive constriction, external struc- 
tural reinforcement of grafts has also been pro- 
posed. 17 
Numerous pharmacologic agents have been 
identified that inhibit platelet adhesion and aggre- 
gation, events that are of primary importance for 
vascular hemostasis. For short-term anticoagulant 
therapy, heparin is widely administered. To achieve 
systemic effects, standard heparin should to be given 
by continuous intravenous infusion or by regular 
subcutaneous injections two or three times daily. 
The use of systemic heparin may be associated with 
acute complications such as hemorrhage, anaphy- 
laxis, thrombocytopenia, and delayed embolus and 
with chronic complications including alopecia, os- 
teoporosis, pathologic fracture, and ascorbic acid 
deficiency) s These complications preclude the use- 
fulness of long-term heparin therapy in vascular 
surgery. However, local infusion of heparin in small 
amounts may be useful for certain long-term in- 
dications while avoiding systemic side-effects. Re- 
cently, we have designed and characterized a novel 
ePTFE-based local infusion device that can deliver 
therapeutic agents uch as heparin directly through 
the wall of a synthetic graft, thereby achieving high 
drug concentrations in the blood fluid boundary 
layer along the graft wall and at downstream anas- 
tomotic sites. In this study we established in a rabbit 
model the feasibility of inferior vena cava (WC) 
replacement with this approach and evaluated the 
effects of locally infused heparin on graft patency 
and the development of anastomotic neointimal 
hyperplasia. 
MATERIAL AND METHODS 
Infusion device preparation. Local infusion of 
heparin was performed with a device that was 
designcd to deliver the infusatc in a manner that 
achieves highest concentrations within the circum- 
ferential blood boundary layer adjacent to the wall of 
the device downstream from the infusion sitc, as 
previously described. 19Briefly, the device was con- 
structed from microporous ePTFE (4.0 mm internal 
diameter [ID], 30> internodal distance) clinical 
vascular graft material (Gore-Tex*). A cußreservoir 
composed of a 5 mm-long ring of silicone rubber 
tubing (Silastic; Dow Corning, Midland, Mich.) was 
placed over the ePTFE graft and secured in place with 
Silastic adhesive. Heparin was infused into the 
reservoir space between the Silastic ring and the 
ePTFE graft exterior through a length of 1 mm ID 
Silastic tubing inserted through the wall of the 5 mm 
ID Silastic cuff. The infused drug thus filled the 
reservoir, passed through the wall of the porous 
ePTFE graft, and entered the slow moving blood 
layers at the interface between the blood and the graft 
wall (Fig. 1). This concept was validated by compu- 
rational fluid dynamics and documented by in vitro 
flow visualization studies and local sampling tech- 
niques. An implantable osmotic pump (model 2ML; 
Alza Co., Palo Alto, Calif.) was connected to the 
tubing of the devicc. These osmotic pumps reliably 
deliver at a predictable rate of 2.5 I*1 per hour over a 
period of 28 days. Pumps for experimcntal animal use 
were loaded with heparin (20,000 units/2 ml; 
Elkins-Sinn, Inc., Cherry Hill, N.J.), whereas con- 
trols were loaded with sterile saline solution (2 ml). 
Each animal in the heparin-treated group received 
local infusion of heparin at the rate of 30 units/hour, 
which was equivalcnt o an average rate of 7 
tmits/kg/hr. Satisfactory drug delivery was confirmed 
at the time of harvest by observations of pump 
residual volume and grafted vessel patency. 
Animal care and procedure. Twelve male New 
Zealand white rabbits weighing 4.5 + 0.3 kg were 
used in this study. All animal care and procedures 
were in accordance with the "Principles of Labora- 
tory Animal Care" (formulated by the National 
Society for Medical Research) and the Guide for the 
Care and Use of Laboratory Animals (NIH Publication 
No. 80-23, revised 1985). Animals were assigned 
either to a control group that received botmdary layer 
infusion with saline solution (n = 6) or to a treat- 
ment group that received heparin (n = 6). 
General anesthetic was provided for all surgical 
procedures by induction with 3% isoflurane and was 
maintained with 1% to 2% isoflurane inhalation with 
endotracheal positive prcssure ventilation. Under 
sterile conditions a midline abdominal incision was 
made extending about 7 cm. An approximate 5 cm 
segment of IVC was dissected and clamped proxi- 
mally and distally. One centimeter of IVC was 
excised. The ePTFE-based infusion deyice (2.5 cm in 
length, 4.0 mm ID) was anastomosed in an end-to- 
end fashion to the IVC with a running 7-0 Prolene 
*Gore-tex is a trademark ofW. L. Gore & Associates, Elkton, Md. 
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A 
Fig. 1. ePTFE-based local infusion device. A, D vice consists ofsilicone rubber cuff-reservoir 
glued in position between two rings of ringed 4 mm ID ePTFE graft (30 Ixm internodal 
distance). Hub is attached to I mm ID silicone rubber catheter mbing, which is then attached 
to osmotic pump. B, Soluble agent from osmotic pump will pass through graft wall, enter blood 
stream in highest concentration at graft wall (boundary layer), and be transported downstream 
(axially) by blood flow (convection), withslower mixing in radial direction (i.e., toward 
centerstream blood flow) occurring primarily through diffusive mechanisms. Lon, g a~om 
indicates direction of blood flow. 
suture. The technical adequacy of the anastomoses 
was assayed by intraoperative ultrasonic flow mea- 
surements (model T201, 2-channel; Transonic Sys- 
tems Inc., Ithaca, N.Y.). The osmotic pump was 
connected to the tubing of the infusion device and 
immobilized with a few sutures in the right posterior 
wall of the peritoneal cavity (Fig. 2). The incision was 
closed with 3-0 Vicryl sumre (Ethicon, Inc., Som- 
erville, NJ.). The 5'-bromo-3'-deoxyuridine (BrdU, 
25 mg/kg) (Sigma chemical Co., St. Louis, Mo.) 
dissolved in 20 ml saline solution was injected into 
the peritoneal cavity 24 hours before sacrifice. At 14 
days, animals were anesthetized with ketamine and 
xylazine (30 mg/kg and 6 mg/kg, intramuscularly, 
respectively). The implanted ePTFE grafts and IVC 
segments were carefially dissected. Patency of grafts 
was determined by direct inspection, venous strip 
testing blood flow measurement, and later by his- 
tologic analysis. The grafts with 3 cm adjacent IVC 
segments were then harvested and submitted for 
histologic analysis. Finally, the animals were killed 
by an intravenous injection of saturated potassium 
chloride. Blood was drawn for activated partial 
thromboplastin nme (aPTT) assay both before graft 
implantation and at 14 days. 
Histologic study and morphometry. All of the 
harvested grafts were fixed in Carnoy's fixative 
(6:3 : 1 mixmre of ethanol, chloroform, and glacial 
acetate) for 24 hours. After fixation, the grafts were 
cut transversely in series at 3 mm intervals and 
processed through graded ethanol, infiltrated with 
xylene and paraffin, and then embedded in paraffin 
blocks. Five-micrometer sections were cut and 
stained with hematoxylin and cosin and Verhoeff- 
Masson's tain. Cell ingrowth overlying the luminal 
surface of the graft adjacent to the anastomoses was 
considered tobe neointima. Morphometric measure- 
ments of the thickness and area of neointima were 
performed by computer image analysis software 
(Optimas; Bioscan, Inc., Edmonds, Wash.) on a 
magnified image relayed from a microscope- 
mounted video camera to a digitizing pad and video 
monitor (Thomas Optical, Columbus, Ga.). Thick- 
ness was determined ateight different fields around 
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Fig. 2. Configuration for device implantation. 
the graft and was averaged m a mean thickness in each 
section. Area was measured by manually tracking the 
perimeter of neointima, with automated computa- 
tion of total neointimal area in each section. 
Immtmocytochemistry. The avidin-biotin com- 
plex immunoperoxidase procedure (LSAB Kit; Dako 
Co., Carpinteria, Calif.) was used to identify deter- 
minants characterizing vascular smooth muscle cells 
(SMCs) and proliferating cells. To identify SMCs, we 
used HHF-35 monoclonal antibody (Dako Co.), 
which recognizes specific ~-actin. 2° Proliferating cells 
were identified with anti-BrdU monoclonal antibody 
(Dako Co.). 21,22 The sections were heat fixed in a 
60 ° C oven for 60 minutes, deparaffinized, and 
rehydrated. To consume endogenous peroxidase 
activity, the sections were immersed in 3% H202 for 
5 minutes. The sections were treated with proteinase 
K (Dako Co.) for 5 minutes. To expose the nuclear 
binding sites for the BrdU stain, the sections were 
incubated in 2N HC1 at 60 ° C for 45 minutes. The 
sections were incubated with a 1:50 dilution of 
primary monoclonal antibody for 30 minutes. The 
secondary antibody, consisting of rabbit anti-mouse 
conjugated with biotin, was applied for 20 minutes, 
and then streptavidin conjugated with horseradish 
peroxidase was also applied for 20 minutes. The color 
was developed by incubation in the substrate (0.04% 
diaminobenzidine in 0.05 mol/L tris, pH 7.6, with 
0.01% H202). The sections were counterstained in 
nuclear fast red, dehydrated, cleared, and mounted 
in Permount (Fisher Chemicals, Pittsburgh, Pa.). 
BrdU-positive cells were quantified manually with a 
cell counting technique per high-power field ( x 400) 
on a micrometer grid. In each field, all cells were 
counted, and the number of positively stained cells 
was expressed as a percentage oftotal cells to arrive at 
the BrdU index. At least 10 fields were quantified per 
section. 
Statistical analysis. Statistical analysis was per- 
formed on a Macintosh Quadra 650 computer with 
the use of Excel 4.0 statistical software (Microsoft 
Corporafion, Redmond, Wash.). Chi-square analysis 
was used to &termine significant difference in pa- 
tency rates between the heparin-infused group and 
the control group. The paired Student's  test was 
used to compare the aPTT values in the treated and 
control groups both before and at 14 days of bound- 
ary layer infusion. The paired Student's t test was also 
used to determine the significance of neointimal 
thickness, neointimal area, and cell proliferation rates 
between the upstream and downstream anastomoses 
within the treated group. Results were considered 
significant if thep value was less than 0.05. 
RESULTS 
Graft patency. At harvest all osmotic pumps 
were functioning, all grafts in the control group were 
occluded (six of six failed), and all grafts in the 
heparin-treated group were patent (six of six patent). 
The volume blood flow rate through the patent grafts 
averaged 27.2 _+ 7.6 tal/min. The local boundary 
layer infusion of heparin resulted in a significant 
increase ofgraft patency as compared with the saline 
solution-treated group (2 = 0.014). 
Measurements of clotting time. The results of 
the aPTT determinations revealed no significant 
difference between measurements taken before graft 
implantation and at 14 days of continuous heparin 
infusion (12.0 + 1.9 seconds versus 10.2 + 2.7 
seconds;p = 0.55). 
Neointimal hyperplasia. Histologic examina- 
tion showed the presence of thrombus in all grafts in 
the control group. Thus grafts taken from control 
animals were excluded from morphometric analysis 
becäuse of likely variable ffects of graft thrombosis 
on the development of neointimal hyperplasia nd 
because it was difficult to distinguish anastomotic 
neointimal hyperplasia from organized thrombus. In 
the heparin-treated group, neointimal hyperplasia 
occurred at both the upstream and downstream 
anastomoses. Morphometric determinations of anas- 
tomotic neointimal thickness and average lesion area 
were reduced significantly (by 88% and 95%, respec- 
tively, p < 0.01 in both cases) at the downstream 
anastomosis a  compared with the upstream anasto- 
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Fig. 3. Anastomotic neointimal hyperplasia. Verhoeff-Masson's stain. Collagens are blue, 
elastin is black, and others are red. A, Upstream anastomosis infused with heparin. B, 
Downstrearn anastomosis infused with heparin. L represents lumen; N represents neointima. 
(Original magnification x 40.) 
mosis (Table I and Fig. 3). The major ceilular 
component in the neointima was SMC, as identified 
by ci-actin immunostaining. 
Cell proliferation. Vascular SMC proliferation 
was determined by BrdU immunostaining. The use 
of intraperitoneal BrdU was reliable and effective in 
this animal model. We did not experience significant 
labeling problems as a result of interanimal variabil- 
ity. The BrdU labeling index was ignificantly higher 
(p = 0.001) in the neointimal tissue at the upstream 
anastomoses (25% _+ 6%) as compared with the 
downstream anastomoses (7% +- 2%), indicating 
that the local boundary layer infusion of heparin 
reduced neointimal SMC proliferation by about 72% 
(Table I and Fig. 4). 
DISCUSSION 
It is weil known that standard clinical ePTFE 
grafts (30 t*m internodal distance) are impervious to 
the leakage of blood elements as a result of their 
hydrophobic nature and do not require preclotting to 
prevent blood loss through the graft wall. However, 
solutes external to the graft wall will traverse the wall 
as the external pressure exceeds the intraluminal 
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Fig. 4. Cell proliferation in anastomotic neointimal hyperplasia. Immunoperoxidase staining 
of BrdU-labeled cells. Dark brown colar represents positive staining result. A, Upstream 
anastomosis infused with heparin. B, Downstream anastomosis infused with heparin. L 
represents lumen; N represents neointima. (Original magnification ×400.) 
pressure. When a graft is placed in a blood vessel, 
solutes enter the blood stream in highest concentra- 
tion at the graft wall (graft-blood interface) and are 
transported downstream (axially) by the blood flow 
(convection), with slower mixing in the radial 
direction (i.c., toward the centerstream blood flow) 
occurring primarily through diffusive mechanisms. 
This concept has been supported by previous com- 
putational and experimental studies (unpublished 
data, 1994). 19 Computational fluid dynamics was 
used to calculate the infusate concentration  the 
graft wall (see below). Experimental techniques such 
as flow visualization and local sampling were also 
used to document high infusate concentrations along 
the wall downstream from the graft. To calculate 
local wall concentrations of infused agents, the 
equations for fluid flow and mass transport (which 
cannot be solved analytically) were used. The Navier- 
Stokes equations (equations for blood flow motion) 
along with the species conservation equation (the 
equation governing ding convection and diffusion in 
blood) were solved numerically by computer. Labo- 
ratory measurements were also performed by infus- 
ing Evans blue dye and sampling the boundary layer 
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Table I. Effect of heparin on downstream anastomotic neointimal hyperplasia and cell proliferation 
Downstrenm Upstream p Value ~ Reduction 
Neoint imal  thickness 0.144 _+ 0.074 mm 0.658 _+ 0.192 mm 0.006 88% 
Neoint imal  area 0.415 + 0.209 mm 2 2.779 -+ 0.239 mm 2 0.008 95% 
Cell prol i feration 7% -- 2% 25% -- 6% 0.001 72% 
*Ap value less than 0.05 is considered significant. 
through porous graft segments placed at various 
distances downstream. The theoretical and labora- 
tory measurements for the dye infusion were in 
agreement +_10% (unpublished ata, 1994) and 
were used to estimate local hcparin concentrations i  
these exl?eriments. Consistent with these observa- 
tions are the results reported in a porcine arteriove- 
nous shunt model, where local delivery of an 
antithrombin with this method was shown to be 
remarkably efficient for inhibition of thrombus 
formation. 19 
In this study, this approach as been evaluated for 
preventing early thrombosis, preserving raft pa- 
tency, and reducing anastomotic neointimal hyper- 
plasia. Striking effects on these outcome vents were 
achieved in a rabbit model of IVC replacement by 
locally delivering heparin through the wall of the 
prosthesis itself, thereby concentrating the infused 
agent selectively into the slowest moving blood layers 
directly in contact with the graf* and downstream 
vessel wall. Thus in this model (27 ml/min blood flow 
through a4.0 mm ID tube) the infusate is predicted 
to be diluted about 1000-fold along the graft wall at 
a distance of i cm downstream according to theo- 
retical modeling of mass transport under these flow 
conditions. Because the infusate concentration of 
heparin was 10,000 units/ml, the concentration of
heparin along the graft wall and downstream anas- 
tomosis is calculated to have been approximately 10
units/ml, a level expected to produce profound 
inhibition of both coagulation and vascular cell 
proliferation. 23-2s The average infusion rate of hepa- 
rin in the experimental animals was 0.5 units/min. If 
this amount were infused to mix uniformly with all of 
the incoming blood (27 ml/min), the mean heparin 
concentration at all points within the graft would 
have been 0.019 units/ml (0.5 units/min + 27 
ml/min), that is, heparin levels along the graft wall 
would have been about 500-fold lower than those 
achieved by the boundary layer infusion approach. 
The consequences ofheparin recirculation can also be 
readily evaluated. On the basis of estimates of the 
half-life of heparin in vivo (tl/2 = 1 hour) and rabbit 
plasma volume (about 40 ml/kg), the steady-state 
plasma heparin level is directly calculated according 
to first-order clearance kinetics as 0.2 units/ml, a 
minimally anticoagulating dose whose predicted level 
is consistent with the absence of detectable effects 
observed on the aPTT clotting time measurements 
(see Results). The ratio of the local boundary layer 
heparin lcvel (10 units/ml) to the systemic circulating 
levcl is thus estimated as 50:1 eren in this small 
animal model, indicating that with this method very 
high drug levels can be localized to a target vessel 
surface while at the samc time minimizing systemic 
bleeding or other unwanted side-effects. Mthough 
currently we do not have an effective means for local 
sampling and directly measuring the boundary layer 
drug concentration in vivo, the results from this and 
other animal experiments are consistent with predic- 
tions based on in vitro smdies and computational 
modeling. 19 
There has been controversy over the significance 
of postoperative patency duration and its predictabil- 
ity of long-tcrm patency in rein replacement 
procednres. 26-28 There appears to be a critical period 
of approximately 1 to 2 weeks after venous graft 
implantation when the conduit is at particular risk for 
thrombosis. The hypothesis  that if during this time 
cndothelialization ccurs the hazards of thrombosis 
may be avoided. Therefore adjuvant techniqucs that 
prolong early patency, such as the creation of an 
adjacent arteriovenous fi tula or anticoagulation r
both, may result in a higher incidcnce of long-term 
patency. Once the critical period has passed, the 
fistula and anticoagulants may be discontinued. 
Haimovici et al.13 emphasized these principles and 
further defined the 1- to 2-week critical period after 
graft placement during which adjunctive techniques 
could be used to improve long-term patency. Sys- 
temic anticoagulation, however, carries a potential 
risk of bleeding. This limits the use of prosthetic 
conduits for venous reconstruction, particularly in 
cases of tissue trauma, where the use of anticoagulant 
therapy would not be desirable. 29 In this smdy, we 
provide a new strategy to prcvent early graft throm- 
bosis without systemic anticoagulation. I  this first 
report, we selected 14 days as the end point. This 
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time period was selected specifically to document 
feasibility for preventing raft thrombosis by this 
method, hitherto regarded as the principal cause of 
venous conduit failure. Although we have not yet 
determined outcomes for periods greater than 2 
weeks, this approach could be extended for much 
longer-term local infusion therapy if this were 
necessary for maintalning long-term patency. 
An alternate approach to improving patency is 
the use of heparin-bonded prosthetic devices. 3°,31 
Haimovici et al) 3 pointed to antithrombotic sur- 
faces as a potential area of investigation i venous 
prostheses after the early reports of Salzman et al? 2 
and Gott et al. 33 using heparin-bonded synthetics 
in canine vena cava. Najjar and Gott, 31 using the 
canine intrathoracic IVC as a test site, found im- 
proved 2-month patency of woven Dacron (from 
0% to 100%) with tridodecyl methylammonium 
chloride-heparin bonding. However, Wright et al? 4 
could not demonstrate such improvement. They and 
others have questioned the stability of tridodecyl 
methylammonium chloride-heparin complexes on 
synthetic grafts. Elution of heparin, particularly in 
high shear (flow) situations, has been shown. 35'36 
Organic bonding procedures can also result in 
distortion of some polymers, although newer meth- 
ods may alleviate this problem. 37 In this smdy, we 
used transgraft local infusion of heparin through a 
small-caliber PTFE graft to the boundary layer of 
the downstream anastomosis, increasing the early 
(2-week) patency rate from zero to 100% without 
any detectable side effects. 
In addition to the potent anticoagulant effect of 
heparin, it is well established that heparin and 
heparin-like substances can inhibit SMC growth in 
vitro and suppress intimal hyperplasia in animal 
models of arterial injnry. 38'39 Animal studies with 
either air-drying denudation or balloon catheter 
injury techniques have demonstrated suppression of 
arterial SMC growth by intravenous heparin infu- 
sion? 8 This form of gross endothelial denuding 
injury results in the early development of intimal 
hyperplasia,  process that can be decreased signifi- 
cantly by the use of both intravenous tandard 
heparin and heparin-like glycosaminoglycans. 4°,41 
The action ofheparin on SMC growth is independent 
of its anticoagulant function because both nonanti- 
coagulant and anticoagulant fractions uppress pro- 
liferation. 23,24 The mechanism ofgrowth inhibition is 
unknown, but it appears to occur late in the prerep- 
licative (G-l) sequence or early in the S phase (DNA 
synthesis).2325 This study provides definitive in vivo 
evidence that local heparin inhibits cell proliferation 
and reduces anastomotic neointimal hyperplasia. The 
use of heparin reduced cell proliferation by 72%, 
neointimal thickness by 88%, and neointimal rea by 
95% at the downstream anastomoses when com- 
pared with the upstream anastomoses. 
There are, however, two limitations in this 
experiment. The duration of the study was 2 weeks, 
and we are therefore unable to comment on the 
prospects for longer-term patency with this adjunc- 
tive modality. Furthermore, the design of the infu- 
sion device used in this experiment delivered heparin 
at the mid-portion of the graft, thus highlighting the 
significant difference in findings between the up- 
stream and downstream anastomoses as a result of the 
minimal delivery of heparin to upstream sites. The 
unchecked development of neointimal hyperplasia at
the upstreaar~ anastomosis may lead to graft failure. 
To overcome this problem, it is possible to modify 
the delivery device to infuse drug immediately 
adjacent to the upstream anastomosis, thereby pre- 
venting graft thrombosis and perhaps reducing 
neointimal thickening at both anastomoses. Further 
study is needed to evaluate the effect ofthis modified 
system for improving long-term patency of small- 
caliber vein replacements. 
Although this approach is presently being used 
exclusively as a research tool, it may have potential 
clinical applications as well. As demonstrated, this 
drug delivery system ay be used in conjunction with 
prosthetic material in venous reconstructive proce- 
dures. Also, it may influence the patency rates of 
arteriovenous grafts or other procedures that carry a 
high risk for localized thrombotic occlusion. FinaUy, 
we are also investigating the transplantation of 
prosthetic and autogenous valves into ePTFE grafts 
infusion devices as a treatment s rategy for venous 
hypertension. 
We thank Ms. Carolyn Suwyn and Ms. Bevcrly Noe for 
laboratory assistance, and Dr. Samer G. Mattar for 
stimulating discussion and assistance in the preparation f
the manuscript. 
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DISCUSSION 
Dr. Stuart I. Myers (Dallas, Texas). All of us as 
vascular surgeons, particularly those who have tried to 
perform venous reconstructions and face that very difficult 
clinical problem, appreciate the innovative nature of this 
rescarch. 
BrdU was givcn as an intrapcritoneal injcction. It seems 
that, depending on the hydration status of the rabbit, the 
absorption of the BrdU could be somewhat sketchy. Why 
not put the BrdU into the infusion pump so the boundary 
layer can have a more uniform stäining of the cells? 
With regard to the statement that autogenous graft 
material of adequate diameter is not available for recon- 
struction of the major veins, the greater superficial femoral 
vein is an adequate method for reconstructing anything in 
the body. This leads me to question the use of your 
technique as the ideal substitute in acute situations; 
particularly in the trauma situation it is particularly 
intriguing to be able to use this type of device to get 
through a difficult period in an ill patient when you can 
come back with a secondary, more formal reconstruction 
with autogenous material. 
You used the aPTT as your measurement in these 
rabbits. Have you measured any thrombin-III levels? This 
is more the direct action of heparin and is not an indirect 
measure as the aPTT. Do you think that the 
antithrombin-III levels fall quickly or do they gradually 
decline in your model? What do you think happens to 
the level of your antithrombin-III over the 2 weeks of 
the infusion? 
Dr. Alan B. Lumsden. Clearly the supeNcial femoral 
rein is the ideal conduit. The problem is that many of these 
patients have venous disease, and one of the challenges in 
dealing with venous disease is that you don't want to 
harvest the collateral vessels ifat all possible, so use ofsome 
sort of prosthetic device would be a means of leaving the 
collateral vessels. 
BrdU is used to label proliferating cells in the anima124 
hours before sacrifice. It is then taken up in the DNA and 
can then be stained for it. There are a variety of ways in 
which one can deliver BrdU. Suffice it to say that we have 
in the past injected it intravenously with variable resuks. 
The intraperitoneal route has provided the best staining. 
The problem with putting it through the infusion device is 
that we would predominantly label the downstream 
anastomosis. 
Is this applicable for trauma? Yes, it may be applicable 
for trauma, but there are obvious concerns in the use of 
prosthetic devices with the risk of infection. 
With regard to your question about antithrombin-III, 
it may be something that we can measure. We tried to keep 
this outcome as clinically relevant as we possibly could. 
That's the reason for measuring aPTrs. 
Dr. Enrique Criado (Chapel Hill, N.C.). I am not 
certain that the authors have proven that the success with 
the grafts is not necessarily a result of the systemic effects 
ofheparin. There are sorne effects ofheparin that cannot be 
measured by changes in the aPTT or antithrombin-3 levels. 
I believe it would have been bet-ter to administer systemi- 
cally the equivalent dose of heparin to the control animals 
to ensure that the systemic effect of heparin is not 
responsible for the patency of these grafts. 
Dr. Lumsden. We certainly can deliver heparin 
systemically. The problem is that we know that the wall 
concentrations of heparin that you can deliver systemically 
are infinitely smaller than you can deliver through the 
boundary layer infusion device. How do I know that? You 
can scale up these glass models and infuse dye into the 
boundary layer with a colorimetric assay to &termine the 
concentration fdye on the wall. It is about 2000 to 3000 
times what can be achieved with systemic infusion. We are 
trying to make a model that doesn't have systemic 
anticoagulation. Now you may still ger some antiprolifera- 
tive effects, but by all the techniques that are currently 
available for assaying the coagulation system, that's not 
what is prolonging the patency of these grafts. 
Dr. Lazar Greenfield (Ann Arbor, Mich.). Does the 
rabbit develop heparin-associated thrombocytopenia? 
What would you do if your model developed thrombocy- 
topenia? Do you have any evidence that you're producing 
a boundary layer effect becanse flow in the vena cava below 
the level of the renal veins is not laminar? Is there anything 
that you can show us that would demonstrate hat you are 
infusing only at the boundary layer? 
Dr. Lumsden. I have no idea if rabbits develop 
heparin-induced thrombocytopenia, but clearly that would 
be a concern in trying to move this into the clinical arena. 
Obviously you'd have to monitor platelet counts. What 
would you do if the patient's platelet count started 
dropping? You would have to take that pump out. In the 
future, when this is used in a clinical situation, but it will 
have to involve some sott of subcutaneous pump that 
potentially isrechargeable, and you'd have to have access to 
that so that orte could interrupt the flow. That's where this 
is an advantage over heparin-bonded grafts. If the patient 
has a heparin-bonded graft and you have heparin-induced 
thrombocytopenia, then you are in a lot more trouble. 
We have fairly extensively studied the infusion charac- 
teristics of this device. Support for the boundary layer 
concept comes from both computational nd experirnental 
studies. 
Dr. Thomas M. Bergamlni (Louisville, Ky.). One of 
the major problems with any kind of a drug prosthetic 
device is that the drug does not maintain adequate l vels for 
an adequate length of time. This model may be able to 
increase or maintain adequate l vels for a longer period of 
time. 
Did you have heparin levels measured in the upstream 
and downstream anastornotic or vein wall segments? Did 
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you show that these ffects were actually due to a difference 
in concentration of heparin in the upstream and down- 
stream vein wall? 
Do you have proofthat i is a transgraft perfusion of the 
heparin into the vein itself; thät is, the mechanism by which 
this osmotic pump works? Does the transudation of 
heparin decrease with time after the graft is implanted, as 
tissue incorporation of the graft occurs? 
Dr. Lumsden. We have done a lot of work with this 
in a variety of models. Most of them were in the arterial 
system. When you take these grafts out, you can look at 
them, and you will see an upstream layer of thrombus just 
as is seen in any PTFE graft. Over the area where the pump 
is loeated and the drug is being delivered it is clear of 
thrombus, so you have a relatively clear ea. We have no 
doubt that this is delivering through the graft. These are 
usually set up on the bench for 24 hours to make sure the 
pump is primed. It takes about 24 hours for these pumps 
to come up to speed, and you can acmally see fluid that 
transudes through the graft, so there is no question that it 
acmally comes through the graft and delivers. 
We did not measure heparin concentrations directly. 
We have measured aPTFs upstream and downstream. The 
problem is that the heparin is not equally delivered 
throughout the flow stream. What you really want to do is 
sample the boundary layer and then sample sequentially 
right through into the center of the graft. 
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